ValuEngine lowered shares of Chemours (NYSE:CC) from a buy rating to a hold rating in a research note published on Monday morning.
CC has been the subject of a number of other reports. Barclays reissued a buy rating and issued a $60.00 price target on shares of Chemours in a research report on Wednesday, December 6th. Morgan Stanley assumed coverage on shares of Chemours in a research report on Tuesday, January 30th. They issued an equal weight rating and a $57.50 price target for the company. BMO Capital Markets assumed coverage on shares of Chemours in a research report on Tuesday, March 27th. They issued an outperform rating and a $68.00 price target for the company. Zacks Investment Research raised shares of Chemours from a hold rating to a strong-buy rating and set a $58.00 price target for the company in a research report on Wednesday, February 21st. Finally, Goldman Sachs cut shares of Chemours from a buy rating to a neutral rating and set a $55.00 price target for the company. in a research report on Wednesday, December 6th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $58.86.
Shares of Chemours stock traded down $1.07 during trading on Monday, hitting $49.01. 352,724 shares of the stock were exchanged, compared to its average volume of 1,866,506. The stock has a market cap of $8,753.86, a P/E ratio of 12.82, a price-to-earnings-growth ratio of 0.58 and a beta of 2.95. Chemours has a 12-month low of $34.70 and a 12-month high of $58.08. The company has a current ratio of 2.12, a quick ratio of 1.55 and a debt-to-equity ratio of 4.74.
In other Chemours news, insider Paul Kirsch sold 13,770 shares of Chemours stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $50.01, for a total value of $688,637.70. Following the transaction, the insider now directly owns 63,093 shares in the company, valued at $3,155,280.93. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Mark Newman sold 29,381 shares of Chemours stock in a transaction on Friday, March 9th. The shares were sold at an average price of $49.19, for a total transaction of $1,445,251.39. The disclosure for this sale can be found here. Insiders own 1.75% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Aurora Investment Counsel acquired a new position in Chemours in the fourth quarter valued at $1,998,000. JPMorgan Chase & Co. increased its stake in shares of Chemours by 11.9% during the third quarter. JPMorgan Chase & Co. now owns 2,201,287 shares of the specialty chemicals company’s stock worth $110,969,000 after acquiring an additional 234,705 shares during the period. Wells Fargo & Company MN increased its stake in shares of Chemours by 30.1% during the third quarter. Wells Fargo & Company MN now owns 266,263 shares of the specialty chemicals company’s stock worth $13,477,000 after acquiring an additional 61,618 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Chemours during the third quarter worth about $3,325,000. Finally, Magnetar Financial LLC increased its stake in shares of Chemours by 119.9% during the third quarter. Magnetar Financial LLC now owns 17,614 shares of the specialty chemicals company’s stock worth $891,000 after acquiring an additional 9,605 shares during the period. Institutional investors own 77.78% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3335222/chemours-cc-stock-rating-lowered-by-valuengine.html.
The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.